Copyright © 2018 Claristock. All Right Reserved
Total Mark
91
Above 70 is preferred
Stock Analysis
| Growth Potential | 100 | |
|---|---|---|
| Profitability | 88 | |
| Financial Strength | 83 | |
| Q4 2019 Result | 92 | |
| Q3 2019 Result | 96 | |
| Result 2019 | 83 |
Growth Estimate
| 20 Estimate | 21 Estimate | |
|---|---|---|
| Revenue Growth (%) | 36.6 | 27.6 |
| EPS Growth (%) | 108.5 | 46.7 |
| ROE (%) | 39.3 | 43.7 |
| P/E (times) | ... | ... |
Market Analysis
| Market Sentiment | 33 | |
|---|---|---|
| Relative Valuation | 98 | |
| Being a Value Stock | 57 | |
| Absolute Valuation | NA |
For more detailed information about Neurocrine Biosciences Inc, please go to Yahoo Finance